Equities Analysts Offer Predictions for CNSY Q3 Earnings

Plus Therapeutics, Inc. (NASDAQ:CNSY) – Stock analysts at Ascendiant Capital Markets lowered their Q3 2026 earnings per share (EPS) estimates for Plus Therapeutics in a research note issued to investors on Thursday, September 10th. Ascendiant Capital Markets analyst E. Woo now anticipates that the company will post earnings of ($0.98) per share for the quarter, down from their prior estimate of ($0.92). The consensus estimate for Plus Therapeutics’ current full-year earnings is ($3.76) per share. Ascendiant Capital Markets also issued estimates for Plus Therapeutics’ Q4 2026 earnings at ($0.91) EPS, FY2026 earnings at ($4.40) EPS, Q1 2027 earnings at ($0.78) EPS, Q2 2027 earnings at ($0.78) EPS, Q3 2027 earnings at ($0.65) EPS, Q4 2027 earnings at ($0.66) EPS and FY2027 earnings at ($3.17) EPS.

Plus Therapeutics (NASDAQ:CNSY) last released its quarterly earnings data on Friday, August 14th. The company reported ($1.31) earnings per share (EPS) for the quarter, missing analysts’ consensus estimates of ($0.96) by ($0.35). The firm had revenue of $0.41 million during the quarter. Plus Therapeutics had a negative return on equity of 394.17% and a negative net margin of 620.70%.

Several other analysts have also recently issued reports on CNSY. Weiss Ratings assumed coverage on shares of Plus Therapeutics in a research report on Tuesday, August 4th. They set a “sell (e+)” rating on the stock. Zacks Research raised Plus Therapeutics from a “strong sell” rating to a “hold” rating in a research note on Tuesday, September 1st. One analyst has rated the stock with a Hold rating and one has given a Sell rating to the stock. According to MarketBeat.com, the stock currently has a consensus rating of “Reduce”.

Plus Therapeutics Price Performance

CNSY stock opened at $2.04 on Thursday. Plus Therapeutics has a 52 week low of $2.00 and a 52 week high of $23.42. The firm has a market cap of $15.48 million, a price-to-earnings ratio of -0.61 and a beta of 1.39.

Plus Therapeutics Company Profile

Plus Therapeutics, Inc is a clinical-stage pharmaceutical company focused on developing targeted radiotherapeutics for difficult-to-treat cancers. The company’s technology is designed to deliver radioactive payloads directly to tumors, with the goal of improving local treatment while limiting exposure to surrounding healthy tissue.

Its lead investigational product is rhenium-186 nanoliposomes, also known as 186RNL, a nanotechnology-based radiotherapeutic being evaluated for recurrent glioblastoma and leptomeningeal metastases.